drugset / Trial / NCT00234572

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572

Phase 2/3 Completed 108 enrolled Ipsen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the effectiveness of lanreotide autogel to placebo after a single injection. Effectiveness and safety were then also assessed following four fixed-dose injections and after one year of treatment given at titrated doses.

Timeline

Start
2000-05
Primary completion
2003-01-03
Completion
2003-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified 60 mg Subcutaneous
Subject Lanreotide Other / unclassified 90 mg Subcutaneous
Subject Lanreotide Other / unclassified 120 mg Subcutaneous

Indications